Back to School: How biopharma can reboot drug development. Access exclusive analysis here

OSI, Probiodrug deal

OSIP subsidiary Prosidion Ltd. (Oxford, U.K.) acquired from Probiodrug a dipeptidyl peptidase-4 (DPP-4) program for metabolic indications

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE